We are live on ! Find out more
ORKA

Oruka Therapeutics
ORKA

17 hedge funds and large institutions have $16.8M invested in Oruka Therapeutics in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

4% less capital invested

Capital invested by funds: $17.5M → $16.8M (-$632K)

19% less funds holding

Funds holding: 21 → 17 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

Holders
17
Holders Change
-4
Holders Change %
-19.05%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$32.9K
2
Millennium Management
Millennium Management
New York
+$31.6K
3
Bank of America
Bank of America
North Carolina
+$6.44K
4
BFA
BlackRock Fund Advisors
California
+$5.8K
5
TRCT
Tower Research Capital (TRC)
New York
+$644

Top Sellers

Rank Fund Capital Flow
1
PAM
Panagora Asset Management
Massachusetts
-$224K
2
RCM
RA Capital Management
Massachusetts
-$122K
3
RA
Royce & Associates
New York
-$80.6K
4
UBS Group
UBS Group
Switzerland
-$4.51K
5
CFA
Camarda Financial Advisors
Florida
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$4.13M – – –
Franklin Resources
2
Franklin Resources
California
$3.52M – – –
VMI
3
VHCP Management II
New York
$3.05M – – –
TCM
4
Tekla Capital Management
Massachusetts
$2.34M – – –
RCM
5
RA Capital Management
Massachusetts
$1.48M -$122K -190 -7%
VM
6
VHCP Management
New York
$1.31M – – –
RA
7
Royce & Associates
New York
$363K -$80.6K -125 -18%
Vanguard Group
8
Vanguard Group
Pennsylvania
$351K – – –
Deutsche Bank
9
Deutsche Bank
Germany
$106K – – –
Goldman Sachs
10
Goldman Sachs
New York
$62K +$32.9K +51 +100%
BFA
11
BlackRock Fund Advisors
California
$42K +$5.8K +9 +15%
Cambridge Investment Research Advisors
12
Cambridge Investment Research Advisors
Iowa
$30K – – –
Millennium Management
13
Millennium Management
New York
$30K +$31.6K +49 New
Bank of America
14
Bank of America
North Carolina
$9K +$6.44K +10 +333%
BIM
15
BlackRock Investment Management
Delaware
$3K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$1K +$644 +1 +100%
PAM
17
Panagora Asset Management
Massachusetts
– -$224K -358 Closed
UBS Group
18
UBS Group
Switzerland
– -$4.51K -7 Closed
CFA
19
Camarda Financial Advisors
Florida
– -$1K -1 Closed
Walleye Trading
20
Walleye Trading
New York
– -$1K -1 Closed

ORKA Hedge Fund Activity: Q3 2016 in Review

17 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2016, worth a combined $16.8M — down 3.6% from $17.5M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ORKA and 1 opened new positions — a net loss of 4 holders — while 2 trimmed existing stakes and 4 added.

The largest buyer was Goldman Sachs, adding an estimated $32.9K. The largest seller was Panagora Asset Management, exiting entirely with an estimated $224K sold.

  • 17 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2016, down from 21 in Q2 2016.
  • Funds reported $16.8M of Oruka Therapeutics stock for Q3 2016, down 3.6% quarter-over-quarter.
  • 1 fund opened new Oruka Therapeutics positions in Q3 2016 and 5 closed out, a net change of -4 holders.
  • The largest Oruka Therapeutics buyer in Q3 2016 was Goldman Sachs, an estimated $32.9K added.
  • The largest Oruka Therapeutics seller in Q3 2016 was Panagora Asset Management, an estimated $224K sold.

Based on aggregated 13F filings for Q3 2016.